Results 71 to 80 of about 2,002,341 (191)

Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Interventional radiology (IR) is a rapidly evolving medical field that combines advanced imaging with minimally invasive techniques for both diagnosis and treatment. Interventional oncology (IO), a subspecialty of IR, focuses on the minimally invasive, image‐guided intervention for cancer and cancer‐related conditions.
Mohamed E. Abdelsalam, Kamran Ahrar, Rahul A. Sheth, Ketan Y. Shah, Steven Yevich, Varshana Gurusamy, Bruno C. Odisio, Alda L. Tam, Armeen Mahvash, Peiman Habibollahi   +9 more
wiley   +1 more source

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma

OncoTargets and Therapy, 2015
Advanced inoperable hepatocellular carcinoma (HCC) conferring a grave prognosis may benefit from yttrium-90 ((90)Y) radioembolization.Thirty patients with advanced inoperable HCC including those with any lesion >8 cm in maximal diameter or multiple bi-lobar lesions (totally more than five lesions), or portal vein thrombosis treated with ...
Leung, TW, Law, MW, Wong, KK, Poon, RTP, Kwong, DLW, Ng, CY, Tong, CC, Luk, MY, Leung, DKC, Lee, VHF   +9 more
openaire   +6 more sources

Five Advances in the Last 50 Years: Liver Malignancies

World Journal of Surgery, Volume 50, Issue 8, Page 2116-2120, August 2026.
Alex B. Blair, Timothy M. Pawlik
wiley   +1 more source

Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post Radioembolization 90Y PET

Frontiers in Oncology, 2014
Background: Radioembolization with Yttrium-90 (90Y) microspheres is becoming a more widely used transcatheter treatment for unresectable hepatocellular carcinoma (HCC).
Shyam Mohan Srinivas, Navin eNatarajan, Joshua eKuroiwa, Bana eBazerbashi, Frank P DiFilippo, Naichang eYu, Shetal N Shah, Gordon eMcLennan, Nancy eObuchowski   +8 more
doaj   +1 more source

Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity. Understanding whether discharge prescriptions influence short‐term outcomes may guide standardized pain‐management strategies.
Hanzhou Li, John Moon, Nathan Sim, Michal Horný, Nicholas Lima, Menelaos Konstantinidis, Deepak Iyer, Sonia Benenati, Judy Gichoya, Janice Newsome, Zachary Bercu   +10 more
wiley   +1 more source

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres

Journal of Applied Clinical Medical Physics, 2017
AbstractThe absorbed doses in the liver and adjacent viscera in Yttrium‐90 radioembolization therapy for metastatic liver lesions are not well‐documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated.
Fallahpoor, Maryam, Abbasi, Mehrshad, Parach, Ali Asghar, Kalantari, Faraz   +3 more
openaire   +2 more sources

Fast Monte Carlo Simulation of ⁹⁰Y Bremsstrahlung using a Kernel-based Photon Source [PDF]

, 2011
In targeted radionuclide therapy using ⁹⁰Y, bremsstrahlung photons can be used for imaging and subsequently for absorbed dose estimation. Monte Carlo simulation is a reliable method to study bremsstrahlung imaging but it takes a long computation time as ...
Zakariah, Suhaili
core  

Yttrium-90 Radioembolization of Colorectal Cancer Liver Metastases

, 2022
The present work aims to review the clinical evidence of survival outcome after treatment of colorectal cancer liver metastases using yttrium-90 radioembolization, existence, and relevance of clinical, imaging, and genomic predictors of treatment ...
Bilotta, Federico, Mariarita Russi, Massimiliano Pacilio, Federico Bilotta, d'Andrea, Edoardo, Russi, Mariarita, Pacilio, Massimiliano, Edoardo d’Andrea   +7 more
core   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 498-527, November/December 2025.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source

Treatment of Hepatocellular Cancer Due to Hepatitis Delta with Yttrium-90 Radioembolization in a Patient with Cirrhosis: A Case Report

, 2014
Cirrhosis due to delta hepatitis is one of the most important etiologic factors in our country. Hepatocellular carcinoma (HCC) often develops on the base of cirrhosis.
UYANIKOĞLU, AHMET, Ermis, Fatih, AKYÜZ, Filiz, KAYMAKOĞLU, Sabahattin   +3 more
core   +1 more source